A single centre, double blind, randomised, parallel group, single dose signal study of R-107 in particpants with DSM-5 specific phobia, to spiders.
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 22 Jul 2019
Price : $35 *
At a glance
- Drugs Ketamine (Primary)
- Indications Phobic disorders
- Focus Therapeutic Use
- Sponsors Douglas Pharmaceuticals
- 22 Jul 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 23 Aug 2018 New trial record